IN8bio (IN8bio) 12-1 Month Momentum % : -68.25% (As of Jun. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is IN8bio 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-06-05), IN8bio's 12-1 Month Momentum % is -68.25%.

The industry rank for IN8bio's 12-1 Month Momentum % or its related term are showing as below:

INAB's 12-1 Month Momentum % is ranked worse than
84.8% of 1480 companies
in the Biotechnology industry
Industry Median: -24.245 vs INAB: -68.25

Competitive Comparison of IN8bio's 12-1 Month Momentum %

For the Biotechnology subindustry, IN8bio's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IN8bio's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where IN8bio's 12-1 Month Momentum % falls into.

IN8bio (NAS:INAB) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IN8bio (NAS:INAB) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

IN8bio 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of IN8bio's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

IN8bio (IN8bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

6JH:Germany

Address

350 5th Avenue, Suite 5330, New York, NY, USA, 10118

Website

https://www.in8bio.com

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

Executives

Jeremy R. Graff	director	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall	officer: Chief Financial Officer	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho	director, officer: President, CEO and CFO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l.	director, 10 percent owner	40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc	10 percent owner	10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb	officer: EVP and CSO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami	officer: Chief Medical Officer	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin	officer: Chief Operating Officer	IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118